Misplaced Pages

Bifeprunox

Clinical data
ATC code	none
Identifiers
IUPAC name 7--1,3-benzoxazol-2(3H)-one
CAS Number	350992-10-8
PubChem CID	208951
ChemSpider	181044
UNII	AP69E83Z79
ChEMBL	ChEMBL218166
CompTox Dashboard (EPA)	DTXSID80188592
Chemical and physical data
Formula	C24H23N3O2
Molar mass	385.467 g·mol
3D model (JSmol)	Interactive image
SMILES O=C2Oc1c(cccc1N2)N5CCN(Cc4cccc(c3ccccc3)c4)CC5
InChI InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28) Key:CYGODHVAJQTCBG-UHFFFAOYSA-N
(what is this?)  (verify)

Bifeprunox (INN) (code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D₂ receptor agonism with serotonin receptor agonism. It was under development for the treatment of schizophrenia, psychosis and Parkinson's disease.

In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects. An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007. In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."

Pharmacodynamics

Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.

See also

• Aripiprazole
• Pardoprunox

References

1. Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert F, Vacher B (2007). "Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities". J. Med. Chem. 50 (4): 865–76. doi:10.1021/jm061180b. PMID 17300168.
2. "Bifeprunox". go.drugbank.com. Retrieved 2023-11-16.
3. Casey DE, Sands EE, Heisterberg J, Yang HM (October 2008). "Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study". Psychopharmacology. 200 (3): 317–31. doi:10.1007/s00213-008-1207-7. PMID 18597078. S2CID 23291727.
4. Wyeth and Solvay say FDA rejects application for antipsychotic drug bifeprunox. Thomson Financial, August 10, 2007.
5. Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued Archived 2011-07-14 at the Wayback Machine Lundbeck Press Release.

• Drugs not assigned an ATC code
• 5-HT7 agonists
• Atypical antipsychotics
• Phenylpiperazines
• Carbamates
• Benzoxazoles
• Biphenyls
• Abandoned drugs